Clinical Trials /

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

NCT02949843

Description:

This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation. Giving drugs that target other genetic mutations or other specific proteins may work better when a patient has cancer caused by a driver mutation and the treatment that targets that mutation stops working.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Terminated

Phase:

Phase 2

URL:

https://clinicaltrials.gov/show/NCT02949843

Trial Eligibility

Document

Title

  • Brief Title: Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
  • Official Title: Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers

Clinical Trial IDs

  • ORG STUDY ID: IRB00041150
  • SECONDARY ID: NCI-2016-01589
  • SECONDARY ID: CCCWFU 62716
  • SECONDARY ID: P30CA012197
  • NCT ID: NCT02949843

Conditions

  • EGFR Activating Mutation
  • Recurrent Non-Small Cell Lung Carcinoma
  • Stage IV Non-Small Cell Lung Cancer

Interventions

DrugSynonymsArms
ChemotherapyChemo, Chemotherapy (NOS), Chemotherapy, Cancer, GeneralArm II (kinase inhibitor, chemotherapy, immunotherapy)
ImmunotherapyImmunologically Directed TherapyArm II (kinase inhibitor, chemotherapy, immunotherapy)
NivolumabBMS-936558, MDX-1106, NIVO, ONO-4538, OpdivoArm I (nivolumab, pembrolizumab)
PembrolizumabKeytruda, Lambrolizumab, MK-3475, SCH 900475Arm I (nivolumab, pembrolizumab)
Targeted Molecular Therapymolecularly targeted therapyArm III (kinase inhibitor, targeted therapy, other treatment)
Tyrosine Kinase InhibitorProtein Tyrosine Kinase Inhibitors, PTK Inhibitors, TK InhibitorsArm II (kinase inhibitor, chemotherapy, immunotherapy)

Purpose

This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation. Giving drugs that target other genetic mutations or other specific proteins may work better when a patient has cancer caused by a driver mutation and the treatment that targets that mutation stops working.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To estimate the objective response rate among patients with high PD-L1 expressing cancers
      after failure of targeted therapy.

      SECONDARY OBJECTIVES:

      I. To compare the overall survival for patients receiving treatment targeting primary
      mutations, secondary mutations, or immunotherapy at the time of progression on tyrosine
      kinase inhibitor therapy.

      II. To assess the incidence of secondary mutations in this population according to smoking
      status.

      III. To evaluate the response rates of patients treated using these different approaches.

      IV. To correlate outcomes with specific secondary genetic changes.

      OUTLINE: Patients are assigned to 1 of 3 treatment arms.

      ARM I (PD-L1 >= 50%): Patients receive nivolumab intravenously (IV) over 60 minutes every 2
      weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable
      toxicity.

      ARM II (PD-L1 < 50% without secondary oncogenic driver): Patients receive tyrosine kinase
      inhibitor therapy orally (PO) targeting the initial oncogenic driver or other treatment for
      about 3 weeks.

      ARM III (PD-L1 < 50% with secondary oncogenic driver): Patients receive tyrosine kinase
      inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary
      mutation, or other treatment for about 3 weeks.

      After completion of study treatment, patients are followed up for a minimum of 30 days.

Trial Arms

NameTypeDescriptionInterventions
Arm I (nivolumab, pembrolizumab)ExperimentalPatients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
  • Nivolumab
  • Pembrolizumab
Arm II (kinase inhibitor, chemotherapy, immunotherapy)ExperimentalPatients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
  • Chemotherapy
  • Immunotherapy
  • Tyrosine Kinase Inhibitor
Arm III (kinase inhibitor, targeted therapy, other treatment)ExperimentalPatients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
  • Chemotherapy
  • Immunotherapy
  • Targeted Molecular Therapy
  • Tyrosine Kinase Inhibitor

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed incurable non-small cell
             lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2,
             translocation in Alk, or translocation in ROS-1

          -  Patients must be receiving treatment or planning to start treatment with a tyrosine
             kinase inhibitor targeting the activated gene

          -  Patients may not be receiving the treatment targeting the activated gene as part of a
             clinical treatment trial other than the Precision Oncology Trial

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

          -  Total bilirubin =< 1.5 X institutional upper limit of normal

          -  Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine
             transaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved informed consent document

        Exclusion Criteria:

          -  Emergent need for palliative radiation

          -  Patients may not be receiving any other investigational agents for the treatment of
             non-small cell lung cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded; breastfeeding should be discontinued
Maximum Eligible Age:N/A
Minimum Eligible Age:N/A
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Objective response rate in patients with high PD-L1 expressing cancers after failure of targeted therapy defined as complete or partial response according to the investigator's assessment
Time Frame:Up to 3 years
Safety Issue:
Description:A Simon's two-stage design will be used.

Secondary Outcome Measures

Measure:Incidence of adverse events measured using Common Terminology Criteria for Adverse Events version 4.0
Time Frame:Up to 30 days after the last dose of study treatment
Safety Issue:
Description:Toxicities for each group will be estimated and described using counts and frequencies by grade, location and relatedness.
Measure:Incidence of mutations in secondary genes for patients with PD-L1 expression < 50%
Time Frame:Up to 3 years
Safety Issue:
Description:
Measure:Objective response rates for patients without high PD-L1 expressing cancers
Time Frame:Up to 3 years
Safety Issue:
Description:Objective response rates will be estimates in the two PD-L1 expression < 50% arms. Confidence intervals for each of these rates will be estimated. An exploratory comparison will be made among the three groups comparing complete response/partial response versus stable disease/progressive disease among the groups using a Fisher's exact test (for the 2x3 table).
Measure:Objective response rates for the combined population to historical controls receiving second or third line targeted agents
Time Frame:Up to 3 years
Safety Issue:
Description:Objective response rates will be estimates in the two PD-L1 expression < 50% arms. Confidence intervals for each of these rates will be estimated. An exploratory comparison will be made among the three groups comparing complete response/partial response versus stable disease/progressive disease among the groups using a Fisher's exact test (for the 2x3 table).
Measure:Overall survival
Time Frame:From date of progression on primary targeted treatment to death, assessed up to 3 years
Safety Issue:
Description:Estimated using Kaplan-Meier methods and survival rates will be compared using log-rank tests.
Measure:Rate of tobacco use and mutation burden based on PD-L1 expression at time of progression
Time Frame:Up to 3 years
Safety Issue:
Description:
Measure:Smoking status defined as current, former, never
Time Frame:At baseline
Safety Issue:
Description:Whether smoking status is related to the prevalence of any mutations identified (present/absent) will be examined using Cochran-Maentel Haenzel tests. These tests will be performed overall and then separately in the three arms.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Wake Forest University Health Sciences

Last Updated

January 29, 2021